Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650
Oppenheimer has reiterated its Buy rating for Praxis Precision Medicines (PRAX.US) and maintained its target price at $650. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Praxis Precision Medicines stock hits 52-week high at 388.27 USD
Praxis Precision Medicines (PRAX) stock has reached a new 52-week high of $388.27, marking a 721.64% increase over the past year with a market capitalization of $10.77 billion. Despite being unprofitable, this surge reflects investor confidence and recent positive developments, including a narrower-than-expected Q2 2026 loss and a raised price target from Raymond James. However, InvestingPro data suggests the stock might be overvalued with high volatility.
Praxis Precision Medicines stock hits 52-week high at 388.27 USD
Praxis Precision Medicines Inc. (PRAX) stock has reached a new 52-week high of $388.27, representing a 721.64% increase over the past year. Despite this impressive growth, the company remains unprofitable with an EPS of -$12.86, and InvestingPro data suggests the stock may be overvalued. Raymond James recently raised its price target for PRAX to $945, maintaining a "Strong Buy" rating, citing increased confidence in the company's EMERALD trial and upcoming neurology drugs.
Raymond James raises Praxis Precision Medicines price target on pipeline outlook
Raymond James has increased its price target for Praxis Precision Medicines Inc. (NASDAQ:PRAX) shares from $765 to $945, maintaining a Strong Buy rating. This upgrade is driven by an increased probability of success for the company's EMERALD trial and higher peak sales forecasts for relutrigine, with the firm anticipating significant catalysts in the next 6-12 months including the EMERALD readout, ulixacaltamide's PDUFA date, and its essential tremor launch. Despite the stock's impressive 679% gain over the past year, InvestingPro suggests it may be overvalued.
9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB
Handelsbanken Fonder AB recently acquired 9,840 shares of Praxis Precision Medicines (NASDAQ:PRAX) valued at approximately $3.29 million, contributing to institutional investors owning 67.84% of the company. Praxis Precision Medicines reported a smaller-than-expected quarterly loss of $2.87 per share and holds a consensus "Buy" rating from analysts with an average price target of $573.05. Despite director Jill Desimone selling a significant number of shares, the company's stock opened at $366.81, near its 52-week high.
Praxis Precision Medicines (PRAX): Orbis, Allan Gray disclose 5.5% ownership stake
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly disclosed a 5.5% ownership stake in Praxis Precision Medicines (PRAX), amounting to 1,529,788 shares of common stock as of June 30, 2026. Orbis holds the majority with 1,526,680 shares, while Allan Gray Australia holds 3,108 shares, with both firms exercising sole voting and dispositive power over their respective holdings. This disclosure was made via an amended Schedule 13G/A filing, indicating that they are non-U.S. institutions equivalent to investment advisers.
(PRAX) and the Role of Price-Sensitive Allocations
This article provides a detailed AI-driven analysis of Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting a strong overweight bias across all time horizons. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report also notes an exceptional risk-reward short setup for PRAX.
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month High - Here's Why
Praxis Precision Medicines (NASDAQ:PRAX) recently hit a new 52-week high of $382.97, driven by positive analyst sentiment, including maintained "Buy" ratings and high price targets from HC Wainwright and RBC. The company beat quarterly EPS expectations and is anticipated to have significant catalysts in H2 2026 with potential regulatory decisions and late-stage clinical readouts. Despite near-term cash burn concerns, analysts project a transition from development-stage losses to substantial earnings in the long term.
Equities Analysts Offer Predictions for PRAX Q3 Earnings
HC Wainwright has revised its Q3 2026 EPS estimate for Praxis Precision Medicines (NASDAQ:PRAX) to a loss of $3.86 per share, maintaining a "Buy" rating and a $1,201 price target, indicating expectations for profitability by Q4 2027. Several other analysts also weighed in on the stock, with a consensus "Buy" rating and an average target price of $573.05. The company recently reported a Q3 loss of $2.87 per share, beating consensus estimates, and institutional investors hold a significant portion of its shares.
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201
H.C. Wainwright has reiterated its Buy rating for Praxis Precision Medicines (PRAX.US), maintaining a target price of $1,201. This indicates continued confidence from the firm in the company's future performance.
Dimensional Fund Advisors LP Has $10.04 Million Holdings in Praxis Precision Medicines, Inc. $PRAX
Dimensional Fund Advisors LP significantly increased its stake in Praxis Precision Medicines (NASDAQ:PRAX) by 32.4% in the first quarter, bringing its total holdings to $10.04 million. Institutional investors and hedge funds now collectively own 67.84% of the company, while insiders own 3%. Despite a director's sale of shares, PRAX reported an earnings beat and maintains a "Buy" rating with an average analyst price target of $573.05, though the stock is trading near its 52-week high.
Praxis Precision Medicines, Inc. (PRAX) stock price, news, quote and history
This page provides a comprehensive overview of Praxis Precision Medicines, Inc. (PRAX) stock, including its current price, historical data, key statistics, and company profile. It details the company's focus on developing therapies for CNS disorders and lists its pipeline of clinical-stage and preclinical drug candidates. The article also presents performance metrics, earnings trends, analyst insights, and financial highlights for PRAX.
Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances
Praxis Precision Medicines (PRAX) has achieved a significant milestone with its investigational treatment Elsunersen receiving FDA Breakthrough Therapy designation, advancing its central nervous system pipeline. Despite this regulatory success and other late-stage assets, the company reported substantial net losses and no meaningful revenue in Q2 2026, highlighting that its story remains focused on future potential. Investors should monitor regulatory progress on lead assets and quarterly financial updates to assess the company's balance between R&D investment and potential dilution.
Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances
Praxis Precision Medicines announced significant clinical and regulatory advancements in its central nervous system (CNS) pipeline, including the FDA Breakthrough Therapy designation for Elsunersen. Despite these pipeline successes and expanded collaborations, the company continues to operate with no meaningful revenue and substantial losses, highlighting its reliance on future potential over current cash generation. Investors are advised to monitor regulatory progress on lead assets like relutrigine and ulixacaltamide, as well as financial updates on net loss and share count to assess the sustainability of its strategy.
Praxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% Upside
Praxis Precision Medicines, Inc. (PRAX) has seen its average 12-month stock price target raised to $620.95 by 19 analysts, up from $604.83. This new target suggests a potential upside of approximately 95% from its recent closing price. The consensus analyst rating for PRAX remains a "Buy," with 17 out of 19 analysts recommending a buy.
Glenmede Trust Co. NA Sells 2,878 Shares of Praxis Precision Medicines, Inc. $PRAX
Glenmede Trust Co. NA significantly reduced its stake in Praxis Precision Medicines, Inc. (PRAX) by selling 2,878 shares, retaining 3,410 shares valued at approximately $1.1 million. Despite this, other institutional investors like Swiss National Bank and Geode Capital Management LLC increased their positions. Analysts maintain a "Moderate Buy" rating with a consensus price target of $563.85, even as some have lowered their individual targets.
Praxis Precision Medicines (NASDAQ: PRAX) holds $1.4B cash, advances NDAs
Praxis Precision Medicines reported a Q2 2026 net loss of $83.7 million and a first-half loss of $176.3 million, driven by increased R&D and G&A expenses to fund clinical programs and commercial preparation. Despite these losses, the company holds $1.4 billion in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028. Praxis is advancing its pipeline with NDAs for ulixacaltamide and relutrigine under FDA review, and elsunersen having received breakthrough therapy designation, although one vormatrigine study missed its primary endpoint.
Praxis Precision Medicines stock hits 52-week high at 366.7 USD
Praxis Precision Medicines Inc. (PRAX) has reached a new 52-week high of $366.70, reflecting a 557% one-year return and a market cap of $9.92 billion, despite an InvestingPro analysis suggesting it may be overvalued. The company recently reported a Q2 2026 loss of $2.87 per share, beating analyst expectations, and had positive mid-cycle FDA meetings for two key drugs, ulixacaltamide HCl and relutrigine, with PDUFA dates set for 2027 and 2026 respectively.
Praxis Precision Medicines beats Q2 loss estimates; shares rise
Praxis Precision Medicines Inc. (NASDAQ:PRAX) reported a Q2 loss of $2.87 per share, outperforming analyst estimates. The company's shares rose 6.5% in premarket trading following the news, which also highlighted progress with FDA interactions for its drug candidates ulixacaltamide HCl and relutrigine, and a third Breakthrough Therapy Designation for elsunersen. Praxis reported $1.4 billion in cash and investments, expected to fund operations into 2028.
Praxis Precision Medicines stock hits 52-week high at 366.7 USD
Praxis Precision Medicines Inc. (PRAX) has reached a new 52-week high of $366.70, with shares currently trading at $369.68, reflecting a 557% one-year return. The company's stock is experiencing high volatility, indicated by a beta of 2.78, and despite potential overvaluation, analysts maintain a strong buy consensus. Recent developments include exceeding Q2 loss expectations and positive FDA feedback on ulixacaltamide HCl and relutrigine, with PDUFA dates set for early 2027 and late 2026, respectively.
Q2 2026 Praxis Precision Medicines Inc Earnings Call Transcript
Praxis Precision Medicines Inc. held its Q2 2026 earnings call, discussing positive FDA feedback for ulixacaltamide and relutrigine, and strong financial positioning with $1.4 billion in cash. The company also addressed the setback in its vormatrigine program and reported increased operating expenses and cash burn due to launch preparations. Key points include successful BIMO inspections and a new Breakthrough Therapy Designation for elsunersen, alongside extended PDUFA dates and potential tolerability issues for some products.
Praxis Precision earnings on deck as commercialization nears
Praxis Precision Medicines Inc. is set to report second-quarter results, with investors focused on cash burn and commercial readiness as the company awaits two key FDA drug approval decisions. Analysts have a strong buy rating with significant upside potential. The company's cash runway and progress on clinical trials for relutrigine and ulixacaltamide are critical ahead of upcoming regulatory milestones.
Praxis Precision earnings on deck as commercialization nears By Investing.com
Praxis Precision Medicines Inc. is set to report second-quarter earnings, with investors focused on cash burn and commercialization efforts ahead of two key FDA approval decisions for relutrigine and ulixacaltamide. Analysts anticipate a wider loss for the quarter but maintain a "strong buy" rating with significant upside potential. The company's ability to manage costs and execute its commercial launch strategy will be critical as it approaches potential market entries in late 2026 and early 2027.
29 New Praxis Employees Get Stock Units, Four-Year Vesting
Praxis Precision Medicines (PRAX) announced the grant of restricted stock unit (RSU) awards covering 7,318 common shares to 29 new non-executive employees. These inducement grants, made under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4), will vest in four equal annual installments, contingent on continued employment. This move aims to attract and retain talent, aligning employee incentives with the company's long-term success.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 7,318 shares to 29 new non-executive employees on August 3, 2026. These grants were made under the company's 2024 Inducement Plan as material inducements for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards will vest in four equal annual installments, contingent on continued employment.
Responsive Playbooks and the PRAX Inflection
This article analyzes Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting weak near and mid-term sentiment that contrasts with a positive long-term outlook. The report identifies no clear price positioning signals and notes elevated downside risk. It also provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 7,318 shares of common stock to twenty-nine new non-executive employees. These grants were made under the 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to attract new talent. The awards will vest in four equal annual installments, contingent on continued employment.
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Praxis Precision Medicines, Inc. announced it will report its financial results for the second quarter ended June 30, 2026, and provide a corporate update on Thursday, August 6, 2026, before market open. The company will host a conference call and live webcast at 8:30 am ET to discuss these results and updates. A replay of the webcast will be available on their website for approximately 90 days.
Praxis Precision Medicines Inc (PRAX) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Praxis Precision Medicines Inc (PRAX), which currently holds a financial score of 6.42, ranking 245 out of 384 in the Biotechnology & Medical Research industry. The company's financial status is stable with low operating efficiency. Key financial metrics such as cash and cash equivalents, total assets, total liabilities, and free cash flow have not yet been disclosed by the company, impacting the assessment of its quality of earnings, operational efficiency, growth potential, and shareholder returns.
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced it will report its Q2 2026 financial results and provide a corporate update on Thursday, August 6, 2026, before market open. The company will also host a conference call and live webcast at 8:30 am ET on the same day to discuss the results and update. This event will be accessible via their investor relations website.
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Praxis Precision Medicines, Inc. announced it will release its second-quarter financial results for the period ended June 30, 2026, and provide a corporate update on Thursday, August 6, 2026, before market open. The company will host a conference call and live webcast at 8:30 am ET on the same day to discuss the results and update. A replay of the webcast will be available on their website for approximately 90 days.
Praxis will webcast its second-quarter update Aug. 6 at 8:30 a.m.
Praxis Precision Medicines (NASDAQ: PRAX) announced it will report its Q2 2026 financial results and provide a corporate update on Thursday, August 6, 2026, before markets open. The company will host a conference call and live webcast at 8:30 a.m. ET on the same day to discuss developments and review the quarter. Investors can access the webcast via the company's website, with a replay available for approximately 90 days.
Praxis Precision Medicines Inc (PRAX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Praxis Precision Medicines Inc (PRAX), noting its current risk score of 2.04, which ranks it 242 out of 384 in the Biotechnology & Medical Research industry. The company's beta value of 2.75 indicates higher volatility compared to the S&P 500. The assessment also details various financial risk metrics, including maximum drawdown, volatility, and liquidity.
PRAX Reiterated by BTIG -- Price Target Maintained at $810
BTIG analyst Kambiz Yazdi reiterated a "Buy" rating for Praxis Precision Medicine (PRAX) and maintained an $810 price target despite the stock showing significant overvaluation at a 1114.8% premium to its GF Value™. The stock's GF Score™ of 38/100 highlights concerns in profitability and growth, alongside negative insider activity, urging caution for investors.
PRAX|Praxis Precision Medicines Inc|Price:293.038|Chg%:-2.772
This article provides a comprehensive stock analysis of Praxis Precision Medicines Inc (PRAX), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite a recent weak stock market performance, the company shows strong fundamentals and high institutional ownership, with analysts rating it as a "Buy" with significant upside potential. Praxis is a clinical-stage biopharmaceutical company focused on central nervous system disorders, developing therapies through its Cerebrum and Solidus platforms.
Praxis Precision Medicines Inc (PRAX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides an overview of Praxis Precision Medicines Inc.'s (PRAX) shareholder structure, detailing major shareholders, institutional holdings, and related ETF investments. Key shareholders include Janus Henderson Investors and Perceptive Advisors LLC, with significant institutional ownership changes over recent quarters. The data covers shareholder types, institutional holding trends, and specific shareholder activity.
Praxis Precision Medicines Inc (PRAX) Institutional Confidence
Praxis Precision Medicines Inc (PRAX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional ownership stands at 114.11%, an increase of 24.71% quarter-over-quarter, with Steven Cohen being the largest individual institutional shareholder. Major institutional holders include Janus Henderson Investors, Perceptive Advisors LLC, and BlackRock Institutional Trust Company, N.A.
Orbimed Advisors LLC Raises Position in Praxis Precision Medicines, Inc. $PRAX
Orbimed Advisors LLC significantly increased its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) by 82.5% in the first quarter, now holding 172,500 shares valued at $55.6 million. The company reported a smaller-than-expected quarterly loss of $3.20 per share, surpassing analyst projections of a $3.58 loss. Despite a director selling shares, analysts maintain a "Moderate Buy" consensus rating with an average target price of $563.50, reflecting optimism about the clinical-stage biopharmaceutical firm.
SummitTX Capital L.P. Sells 4,791 Shares of Praxis Precision Medicines, Inc. $PRAX
SummitTX Capital L.P. decreased its stake in Praxis Precision Medicines (NASDAQ:PRAX) by 11.5% in the first quarter, selling 4,791 shares and retaining 36,838 shares valued at $11.9 million. Despite this, institutional investors and hedge funds own 67.84% of the company, with notable increases from Orbimed Advisors and Sei Investments. Praxis Precision Medicines, currently trading at $325.30, exceeded quarterly earnings estimates and holds a consensus "Moderate Buy" rating from analysts with an average price target of $563.50.
Praxis Precision Medicines Inc (PRAX) Balance Sheet - Tradingkey.com
This article from TradingKey.com provides a detailed balance sheet analysis for Praxis Precision Medicines Inc (PRAX), including quarterly and annual financial statements. It covers key metrics such as cash and short-term investments, total assets, liabilities, and shareholders' equity. The data allows investors to evaluate the company's financial health, liquidity, leverage, and return on equity.
TradingKey
This page provides the quarterly and annual income statement for Praxis Precision Medicines Inc. (PRAX), detailing financial performance metrics such as total revenue, operating expenses, operating profit, net non-operating interest income, income before tax, and net income. It also includes frequently asked questions about interpreting income statements and specific financial figures for PRAX.
Swiss National Bank Acquires 6,200 Shares of Praxis Precision Medicines, Inc. $PRAX
The Swiss National Bank increased its stake in Praxis Precision Medicines (NASDAQ:PRAX) by 15.3% in the first quarter, purchasing an additional 6,200 shares to bring its total holding to 46,700 shares valued at approximately $15 million. This move comes as other institutional investors have also adjusted their positions in the company. Analysts generally maintain a "Moderate Buy" consensus rating for PRAX, with an average price target of $563.50, despite recent price target adjustments from some firms.
Fifth Third Bancorp Acquires New Holdings in Praxis Precision Medicines, Inc. $PRAX
Fifth Third Bancorp has acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX), purchasing 3,589 shares valued at $1,156,000 during the first quarter. This comes as other institutional investors have also adjusted their holdings, and despite a recent insider sale by a director. The company has a "Moderate Buy" average analyst rating with an average price target of $563.50.
Allspring Global Investments Holdings LLC Grows Stake in Praxis Precision Medicines, Inc. $PRAX
Allspring Global Investments Holdings LLC significantly increased its stake in Praxis Precision Medicines, Inc. ($PRAX) by 392.8% in the first quarter of 2026, bringing their total holdings to 8,536 shares valued at $2,725,000. Other institutional investors also adjusted their positions in the company. Analysts have provided a "Moderate Buy" consensus rating for PRAX with an average price target of $563.50, despite a recent insider selling 11,600 shares.
PRAX|Praxis Precision Medicines Inc|Price:325.300|Chg%:+2.900
Praxis Precision Medicines Inc (PRAX) is a clinical-stage biopharmaceutical company focused on central nervous system disorders, with its stock currently trading at $325.30. The company has strong fundamentals and high growth potential, evidenced by high institutional ownership and multiple "Buy" ratings from analysts with a target price of $603.89. Despite average stock market performance recently, its valuation is considered fairly valued within the Biotechnology & Medical Research industry.
Understanding the Setup: (PRAX) and Scalable Risk
This article analyzes Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting divergent sentiment across different time horizons and suggesting choppy market conditions. It identifies an exceptional 85.2:1 risk-reward setup targeting a 24.6% gain against a 0.3% risk. The analysis provides specific trading strategies (Position, Momentum Breakout, and Risk Hedging) with entry zones, targets, and stop losses, based on AI-generated signals and multi-timeframe analysis.
Praxis Precision Medicines (PRAX) Bank of America Global Healthcare Conference 2026 summary
Praxis Precision Medicines presented at the Bank of America Global Healthcare Conference 2026, outlining its strategy to manage a royalty portfolio of over 100 assets, with a focus on late-stage clinical and commercial assets. The company aims for 20% annual growth from its commercial portfolio, supported by a $1 billion cash position and efficient operations. Key growth drivers include FILSPARI and OHTUVAYRE, with new acquisitions like XOMA expected to significantly expand its portfolio and cash flow.
PRAX stock trades around recent lows as Praxis Precision Medicines updates pipeline and cash runway
Praxis Precision Medicines Inc. (PRAX) is a clinical-stage neuroscience company whose stock is trading near recent lows due to ongoing clinical and financing risks. The company reported a substantial operating loss and a cash runway into early 2026 based on its 2024 financials, with minimal product revenue and increasing R&D expenses. Investors are focused on its pipeline progress in focal epilepsy and movement disorders and the timing of clinical milestones, as future financing needs and potential dilution remain key considerations for the stock's valuation.
Should Praxis–Remagine Transdermal Patch Collaboration and FDA Review Extension Reshape PRAX Pipeline Expectations?
Praxis Precision Medicines' collaboration with Remagine Labs to develop a transdermal patch for ulixacaltamide and the FDA's three-month extension for relutrigine's NDA review are significant developments for the company. These events could positively influence the perception of Praxis's pipeline durability and reach, particularly for its central nervous system portfolio. The company's financial forecasts project substantial revenue and earnings growth by 2029, suggesting a strong upside to its current stock price.
Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs
Praxis Precision Medicines Inc. (PRAX) has announced a research partnership and license agreement with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide delivery, a T-type calcium channel inhibitor for essential tremor. This collaboration aims to leverage Remagine's precise skin-based dosing platform. Additionally, the FDA has granted a three-month extension for the NDA review of Praxis's relutrigine, a treatment for epileptic and SCN2A & SCN8A developmental encephalopathy, with a new PDUFA target date of December 27.
